Patient P-02631
Therapy response
Declining
Tolerance
Stable
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
57%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S17
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability-6
- Inflammatory activity-5
- Toxicity-4
- Nutritional resilience-2
What helped?
No interventions yet.
LIFE OS recommendation
GI Support Protocol GI-04
69%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 87% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- WearableHRV 22 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 58 and rising
- WearableSleep 6.1 h, below personal baseline
- Drug metabolism and exposure ↑20
- BloodToxicity index 51
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.8 · butyrate capacity 39/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 21 ms
- Sleep
- 5.9 h
- Steps
- 4,546
- Resting HR
- 72 bpm
Daily log: GI score 58, nutritional resilience 35, adherence 63.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02084 | 53% | S11 | GI-04 | no change | 58 |
| P-02136 | 52% | S10 | — | — | 63 |
| P-02029 | 51% | S18 | — | — | 56 |
| P-02591 | 50% | S13 | — | — | 68 |
| P-02034 | 49% | S18 | — | — | 61 |
| P-02151 | 49% | S04 | CR-01 | improved | 49 |
| P-02025 | 48% | S15 | CR-01 | improved | 61 |
| P-02111 | 48% | S20 | — | — | 51 |
| P-02046 | 46% | S10 | — | — | 55 |
| P-02250 | 46% | S04 | — | — | 64 |
| P-02530 | 46% | S07 | — | — | 67 |
| P-02054 | 44% | S01 | CR-01 | improved | 57 |